Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 6/2020

10.07.2020 | Case Report

Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography

verfasst von: Nobuhiko Ogasawara, Satoshi Saitoh, Fumitaka Suzuki, Keiichi Kinowaki, Jun Masuda, Hideyuki Denpou, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Yuji Miura, Toshimi Takano, Hiromitsu Kumada

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

A 78-year-old man had received interferon therapy and achieved sustained virologic response for chronic hepatitis C 10 years before. He came to our hospital due to liver damage. Abdominal ultrasonography showed a 90-mm mass lesion in the liver. The echoic level was high in the central part and low in the edge of the tumor. Moreover, there was an accumulation of low echoic irregular mass lesions around the hepatic portal region. Cervical ultrasonography also revealed several 15-mm mass lesions on the left clavicle, the imaging character of which was similar to the liver tumor. The liver tumor seemed to be hypovascular on dynamic computed tomography, but contrast-enhanced ultrasonography showed hyperenhancement at the early vascular phase and at maximum intensity projection showed a treelike branch vascular structure that derived from the central part to the margin of the mass. A needle biopsy of the liver tumor and a cervical lymph node resection were performed, which led to the definitive diagnosis of undifferentiated carcinoma of the liver with multiple lymph node metastasis, upon histological analysis. Undifferentiated carcinoma of the liver is extremely rare and contrast-enhanced ultrasonography was the most useful device for evaluating vascular characteristics in this case.
Literatur
1.
Zurück zum Zitat Nakasuka H, Okada S, Okusaka T, et al. Undifferentiated carcinoma of the liver with neuroendocrine features: a case report. Jpn J Clin Oncol. 1998;28:401–4.PubMed Nakasuka H, Okada S, Okusaka T, et al. Undifferentiated carcinoma of the liver with neuroendocrine features: a case report. Jpn J Clin Oncol. 1998;28:401–4.PubMed
2.
Zurück zum Zitat Shimizu Y, Kaneko F, Motoori T, et al. Undifferentiated hepatocellular carcinoma difficult to distinguish from liver abscess. Intern Med. 2011;50:519–20.PubMed Shimizu Y, Kaneko F, Motoori T, et al. Undifferentiated hepatocellular carcinoma difficult to distinguish from liver abscess. Intern Med. 2011;50:519–20.PubMed
3.
Zurück zum Zitat Watanabe R, Matsumura M, Chen CJ, et al. Gray-scale liver enhancement with Sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull. 2003;26:1272–7.PubMed Watanabe R, Matsumura M, Chen CJ, et al. Gray-scale liver enhancement with Sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull. 2003;26:1272–7.PubMed
4.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50.
5.
Zurück zum Zitat Maeda T, Kayashima H, Imai D, et al. Undifferentiated carcinoma of the liver: a case report with immunohistochemical analysis. Surg Case Rep. 2017;3:12.PubMedPubMedCentral Maeda T, Kayashima H, Imai D, et al. Undifferentiated carcinoma of the liver: a case report with immunohistochemical analysis. Surg Case Rep. 2017;3:12.PubMedPubMedCentral
6.
Zurück zum Zitat Hiraki M, Kitahara K, Miyoshi A, et al. A long-term survivor of undifferentiated carcinoma of the liver successfully treated with surgical treatments: a case report and literature review. Int J Surg Case Rep. 2018;51:45–9.PubMedPubMedCentral Hiraki M, Kitahara K, Miyoshi A, et al. A long-term survivor of undifferentiated carcinoma of the liver successfully treated with surgical treatments: a case report and literature review. Int J Surg Case Rep. 2018;51:45–9.PubMedPubMedCentral
7.
Zurück zum Zitat Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286:29–48.PubMed Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286:29–48.PubMed
8.
Zurück zum Zitat Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol. 2006;186:1401–12.PubMed Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol. 2006;186:1401–12.PubMed
9.
Zurück zum Zitat Murphy-Lavallee J, Jang HJ, Kim TK, et al. Are metastases really hypovascular in the arterial phase? The perspective based on contrast-enhanced ultrasonography. J Ultrasound Med. 2007;26:1545–56.PubMed Murphy-Lavallee J, Jang HJ, Kim TK, et al. Are metastases really hypovascular in the arterial phase? The perspective based on contrast-enhanced ultrasonography. J Ultrasound Med. 2007;26:1545–56.PubMed
10.
Zurück zum Zitat Wilson SR, Jang HJ, Kim TK, et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol. 2008;190:691–5.PubMed Wilson SR, Jang HJ, Kim TK, et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol. 2008;190:691–5.PubMed
11.
Zurück zum Zitat Tanaka H, Iijima H, Higashiura A, et al. New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol. 2014;49:755–63.PubMed Tanaka H, Iijima H, Higashiura A, et al. New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol. 2014;49:755–63.PubMed
12.
Zurück zum Zitat Ohya K, Saitoh S, Kinowaki K, et al. Primary liver carcinoma with sarcomatous changes: analysis of 10 cases. Hepatol Res. 2019;49:711–7.PubMed Ohya K, Saitoh S, Kinowaki K, et al. Primary liver carcinoma with sarcomatous changes: analysis of 10 cases. Hepatol Res. 2019;49:711–7.PubMed
13.
Zurück zum Zitat Frinking P, Segers T, Luan Y, et al. Three decades of ultrasound contrast agents: a review of the past, present and future improvements. Ultrasound Med Biol. 2020;46:892–908.PubMed Frinking P, Segers T, Luan Y, et al. Three decades of ultrasound contrast agents: a review of the past, present and future improvements. Ultrasound Med Biol. 2020;46:892–908.PubMed
14.
Zurück zum Zitat Pinkus GS, Etheridge CL, O’Connor EM. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies. Am J Clin Pathol. 1986;85:269–77.PubMed Pinkus GS, Etheridge CL, O’Connor EM. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies. Am J Clin Pathol. 1986;85:269–77.PubMed
15.
Zurück zum Zitat Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med. 2000;124:1196–200.PubMed Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med. 2000;124:1196–200.PubMed
16.
Zurück zum Zitat Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137–44.PubMed Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137–44.PubMed
17.
Zurück zum Zitat Ogasawara N, Saitoh S, Akuta N, et al. Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. Hepatol Res. 2019;49:1441–50.PubMed Ogasawara N, Saitoh S, Akuta N, et al. Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. Hepatol Res. 2019;49:1441–50.PubMed
Metadaten
Titel
Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography
verfasst von
Nobuhiko Ogasawara
Satoshi Saitoh
Fumitaka Suzuki
Keiichi Kinowaki
Jun Masuda
Hideyuki Denpou
Norio Akuta
Shunichiro Fujiyama
Yusuke Kawamura
Hitomi Sezaki
Tetsuya Hosaka
Masahiro Kobayashi
Yoshiyuki Suzuki
Yasuji Arase
Kenji Ikeda
Yuji Miura
Toshimi Takano
Hiromitsu Kumada
Publikationsdatum
10.07.2020
Verlag
Springer Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 6/2020
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01180-x

Weitere Artikel der Ausgabe 6/2020

Clinical Journal of Gastroenterology 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.